Podcasts about Janssen

Share on
Share on Facebook
Share on Twitter
Share on Reddit
Share on LinkedIn
Copy link to clipboard
  • 862PODCASTS
  • 2,975EPISODES
  • 32mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • May 23, 2022LATEST

POPULARITY

20122013201420152016201720182019202020212022


Best podcasts about Janssen

Show all podcasts related to janssen

Latest podcast episodes about Janssen

Andruck - Deutschlandfunk
Tin Fischer: "Linke Daten, rechte Daten"

Andruck - Deutschlandfunk

Play Episode Listen Later May 23, 2022 6:14


Janssen, Christinawww.deutschlandfunk.de, Andruck - Das Magazin für Politische LiteraturDirekter Link zur Audiodatei

MLOps.community
CPU vs GPU // Ronen Dar & Gijsbert Janssen van Doorn // MLOps Coffee Sessions #99

MLOps.community

Play Episode Listen Later May 20, 2022 63:57


MLOps Coffee Sessions #99 with Ronen Dar and Gijsbert Janssen van Doorn, Getting the Most Out of your AI Infrastructure co-hosted by Vishnu Rachakonda. // Abstract Run:AI is building a cloud-based platform for building with AI. In this talk, we hear all about why this need exists, how this works, and what value it creates. // Bio Ronen Dar Run:AI Co-founder and CTO Ronen was previously a research scientist at Bell Labs and has worked at Apple and Intel in multiple R&D roles. As CTO, Ronen manages research and product roadmap for Run:AI, a startup he co-founded in 2018. Ronen is the co-author of many patents in the fields of storage, coding, and compression. Ronen received his B.S., M.S., and Ph.D. degrees from Tel Aviv University. Gijsbert Janssen van Doorn Gijsbert is Director of Technical Product Marketing at Run:AI. He is a passionate advocate for technology that will shape the future of how organizations run AI. Gijsbert comes from a technical engineering background, with six years in multiple roles at Zerto, a Cloud Data Management and Protection vendor. // MLOps Jobs board https://mlops.pallet.xyz/jobs // Related Links The Hard Thing About Hard Things: Building a Business When There Are No Easy Answers by Ben Horowitz ebook: https://www.scribd.com/book/211302755/The-Hard-Thing-About-Hard-Things-Building-a-Business-When-There-Are-No-Easy-Answers?utm_medium=cpc&utm_source=google_search&utm_campaign=3Q_Google_DSA_NB_RoW&utm_term=&utm_device=c&gclid=Cj0KCQjw1ZeUBhDyARIsAOzAqQLnUzXlgFT1PjU_M6jGqRZmwLbcK-mbfKQI4XrZJBRwgUs4x5j2hQ4aAmt1EALw_wcB --------------- ✌️Connect With Us ✌️ ------------- Join our slack community: https://go.mlops.community/slack Follow us on Twitter: @mlopscommunity Sign up for the next meetup: https://go.mlops.community/register Catch all episodes, blogs, newsletters, and more: https://mlops.community/ Connect with Demetrios on LinkedIn: https://www.linkedin.com/in/dpbrinkm/ Connect with Vishnu on LinkedIn: https://www.linkedin.com/in/vrachakonda/ Connect with Ronen on LinkedIn: https://www.linkedin.com/in/ronen-dar/ Connect with Gijsbert on LinkedIn: https://www.linkedin.com/in/gijsbertjvd/ Timestamps: [00:00] Introduction to Ronen Dar & Gijsbert Janssen van Doorn [01:25] Takeaways [04:24] Thank you Run:AI for sponsoring this episode! [05:13] Run:AI products and components [09:27] Companies coming to Run:AI and problems they solve [13:30] Why is this problem hard? [18:56] Run:AI's Vision [22:12] Run-on-the-mill workload [25:36] Engineering challenges and requirements building Run:AI [32:47] Process of solving problems on the same page [35:45] Power to give data scientists [37:38] Avoiding horror stories that might cost a lot of money [44:23] Running multiple models on a single GPU [47:17] Never scale down to zero [48:28] So many ML Start-ups in Israel [53:00] Vision for the future at GPUs and how will Kubernetes advance [55:55] Future of AI accelerators [57:03] Lightning round [1:02:26] Wrap up

AD Voetbal podcast
S4E199: 'Selectie van Vincent Janssen is belachelijk, waar is Brobbey?

AD Voetbal podcast

Play Episode Listen Later May 15, 2022 43:55


De vierendertig wedstrijden in de eredivisie zitten erop. Dus tijd voor conclusies over dit seizoen in de eredivisie. En dan met name over de strijd tegen degradatie. Heracles waande zich veilig, maar speelt nu tegen degradatie en AZ moet vechten voor Europees voetbal. Etienne Verhoeff bespreekt het in een nieuwe AD Voetbalpodcast met Mikos Gouka en Sjoerd Mossou. In de podcast gaat het natuurlijk over het verval van Heracles de laatste weken en de wederopstanding van Sparta. 'Maurice Steijn trainer van het jaar zei ik na afloop voor de grap. Maar voor Sparta is zijn aanstelling wel een gouden greep', reageert Gouka. 'Clubs die tussentijds van trainer hebben gewisseld doen het opvallend beter dit seizoen', vult Mossou aan. 'Dat is best opmerkelijk. Dat geldt voor Sparta, PEC Zwolle, Willem II en Heerenveen.' Dus is een trainerswissel de redding voor Heracles?  Waar FC Twente boven verwachting presteerde in de eredivisie, presteert AZ onder. Gouka: 'AZ zit in de situatie die Feyenoord vorig jaar had. Je kan op basis van deze cijfers zeggen dat Pascal Jansen het niet goed heeft gedaan.' Mossou: ‘AZ heeft in slotfases op hele knullige wijze punten verloren steeds. Daar moet je als clubleiding van AZ wel naar gaan kijken. En Mossou en Gouka komen nog terug op de voorlopige selectie van Louis van Gaal. Die ruimde een plekje in voor Vincent Janssen. De spits speelt in Mexico de laatste jaren. ‘Belachelijk!', vindt Gouka. 'Van Gaal gooit het systeem om omdat de spelers daar uitstekend bij zouden passen. En na twee wedstrijden komen we tot de conclusie dat we geen spits hebben die het kan. Waarom zit Brobbey dan niet bij Oranje?'  ‘Het laat vooral zien dat Van Gaal nog heel erg aan het zoeken is. Wie moet met Memphis het spitsenduo spelen?' vindt Mossou. Beluister de hele podcast nu via AD.nl, de AD App en natuurlijk jouw favoriete podcastplatform. Support the show: https://krant.nl See omnystudio.com/listener for privacy information.

This Week in Virology
TWiV 899: COVID-19 clinical update #114 with Dr. Daniel Griffin

This Week in Virology

Play Episode Listen Later May 14, 2022 55:56


In COVID-19 clinical update #114, Dr. Griffin discusses early treatment with ivermectin, procalcitonin not a reliable biomarker, vaccine in 6-11 year olds, FDA limits use of Janssen vaccine, does site of vaccine booster matter, sniffer dogs, monoclonals for hospitalized patients, risk assessment for public events, Paxlovid eligibility, and persistence of pediatric anosmia. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Effects of early treatment with Ivermectin (NEJM) Procalcitonin not a reliable biomarker (IDSA) Evaluation of vaccine in children 6 to 11 years (NEJM)) FDA limits use of Janssen vaccine (FDA) Recall of b cell memory on vaccination location (Science Immunology) Persistence screening using sniffer dogs (Journal of Clinical Trials) Tixagevimab/Cilgavimab for treatment of hospitalized patients (Lancet) Infection detection by canine olfaction (OFID) Diagnostic utility to differentiate patients (IDSA) Prevalence of anosmia in pediatric cases (Pediatric Infectious Disease Journal) Risk assessment for public events (University of Texas COVID-19 Modeling Consortium) PAXLOVID patient eligibility screening checklist (FDA) PAXLOVID drug interactions (IDSA) Contribute to ASTMH fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 899 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Pharma Intelligence Podcasts
How Ex-Janssen India Chief Is Steering Bharat Serums' Ambitions In Women's Health

Pharma Intelligence Podcasts

Play Episode Listen Later May 13, 2022 40:32


Sanjiv Navangul, managing director and CEO, Bharat Serums and Vaccines, outlines, in a wide ranging interview, the firm's gameplan to establish itself as a “force to reckon with” in women's health - it goes beyond drugs and encompasses devices and potentially digital therapeutics as well. The former Janssen India chief also weighs in on the worrying industry-wide input cost escalation scenario and supply chain turbulence.

The Jason Gregor Show
May 12, 2022 | Hour 1 | Tom Gazzola - Cam Janssen

The Jason Gregor Show

Play Episode Listen Later May 13, 2022 45:26


May 12, 2022 | Hour 1 | Tom Gazzola - Cam Janssen

MPR Weekly Dose
MPR Weekly Dose 115 — Janus Kinase Inhibitor Approved for COVID-19; Varenicline Supply; Janssen Vaccine Limits Set; Test Safety Alert; Potential Hemodialysis Chemical Exposure

MPR Weekly Dose

Play Episode Listen Later May 12, 2022 11:41


Treatment approved for hospitalized COVID-19 patients; Update on Varenicline supply; Limits have been set for the Janssen COVID-19 vaccine; Safety alert issued for a COVID-19 test; And certain hemodialysis machines may carry the potential for chemical exposure.

Government Of Saint Lucia
No recall of the batch of Janssen COVID-19 vaccine in Saint Lucia

Government Of Saint Lucia

Play Episode Listen Later May 11, 2022 2:23


The Ministry of Health has reviewed the information arising from the alert and recognized that the current batch of Janssen COVID-19 vaccines circulating in SaintLucia is NOT among the recalled batches.

Wirtschaft am Mittag  - Deutschlandfunk
Yasmin Fahimi - Wer ist die neue DGB-Chefin?

Wirtschaft am Mittag - Deutschlandfunk

Play Episode Listen Later May 9, 2022 2:37


Janssen, Hilkewww.deutschlandfunk.de, Wirtschaft am MittagDirekter Link zur Audiodatei

Studio 9 - Deutschlandfunk Kultur
Yasmin Fahimi - Wer ist die neue DGB-Chefin?

Studio 9 - Deutschlandfunk Kultur

Play Episode Listen Later May 9, 2022 3:09


Janssen, Hilkewww.deutschlandfunkkultur.de, Studio 9Direkter Link zur Audiodatei

Psound Bytes
Ep. 164 "Struggling with Self-Esteem and Psoriatic Disease? Could be Body Dysmorphia."

Psound Bytes

Play Episode Listen Later May 3, 2022 20:05


Learn more about body dysmorphia, symptoms and its relationship to psoriatic disease and self-esteem from psychiatrist Dr. Vanessa Cutler with NYU Langone Health and Dept. of Psychiatry at NYU Grossman School of Medicine. Family members listen to this episode to catch behaviors that might indicate when help is needed. Psound Bytes is supported by unrestricted educational grants from AbbVie, Amgen, Bristol Myers Squibb, Janssen, and Lilly. 

Live Yes! with Arthritis
Episode 56: Tackling Arthritis Challenges for Patients of Color

Live Yes! with Arthritis

Play Episode Listen Later May 3, 2022 45:01


People of color face more challenges when it comes to managing arthritis, including delayed diagnosis, ineffective doctor-patient communication, mistrust and under-treatment of pain. In this episode, experts will discuss how health disparities impact arthritis care and their origins. Plus, they'll provide potential solutions to help minority patients better take control of their arthritis. This podcast is brought to you in part by support from AbbVie, Bristol-Myers Squibb, Genentech, Horizon Therapeutics, and Janssen, Johnson & Johnson as supporters of the Arthritis Foundation Diversity and Health Equity Initiative Visit the Live Yes! With Arthritis Podcast site to get show notes and a full transcript: https://arthritis.org/liveyes/podcast We want to hear from you. Tell us what you think about the Live Yes! With Arthritis Podcast. Get started by emailing podcast@arthritis.org. Special Guests: Dr. Ashira Blazer and Dr. Michael Parks.

Podcast Saúde - Agência Radioweb
Saúde recomenda 2ª dose de reforço aos idosos acima de 70 anos

Podcast Saúde - Agência Radioweb

Play Episode Listen Later May 2, 2022 1:25


Idosos acima de 70 anos podem receber uma segunda dose de reforço da vacina contra a covid-19. A recomendação do Ministério da Saúde está em Nota Técnica. A segunda dose de reforço também é indicada para pessoas acima de 60 anos que vivem em instituições permanentes.A orientação da pasta é que o imunizante utilizado seja o da Pfizer quatro meses após a aplicação da primeira dose de reforço. As vacinas da Janssen ou da AstraZeneca podem ser utilizadas de maneira alternativa, independentemente do imunizante utilizado anteriormente. Anteriormente, a segunda dose de reforço era recomendada apenas para idosos acima de 80 anos. 

Stanley on 7th
Breaking Down the Blues with Cam Janssen.

Stanley on 7th

Play Episode Listen Later May 1, 2022 76:02


Carts and King are paid a visit from a true St. Louis Beautician, Cam Janssen. The guys discuss the Wild's first round opponent in detail, and start growing their playoff beards.

Leveraging Thought Leadership with Peter Winick
Ideas, Events, and Behaviors | Ruud Janssen | 390

Leveraging Thought Leadership with Peter Winick

Play Episode Listen Later May 1, 2022 40:19


How can you tell — in an instant — whether an in-person event will be a success or failure? Are there key items that can predict an event's outcome? In-person events are returning, and with them, questions of their utility and ability to really change the behaviors of those who attend. How can a thought leadership practitioner speak about their insights on stage in a way that brings about lasting and sustainable change? In order to better understand the challenges and pitfalls of organizing an event, we've invited Ruud Janssen, the Managing Director and Co-Founder of The Event Design Collective to join us. The Event Design Collective is a group of event designers who train and consult with event owners to elevate events using the Event Canvas model. As the co-creator of The Design Canvas, Ruud shares how they altered Alexander Osterwalder's Business Model Canvas to suit the event space, creating a model that any event owner could use under the creative commons license. Taking an idea and making it shine on stage isn't as simple as it sounds. Ruud helps us grasp the key elements that events need to create value through behavior change. While many concentrate heavily on the look or feel of an event, smart show-runners know that the real selling point is an event's outcome — and how it shapes ideas and habits for those who attend. The most successful events begin by taking notice of the event stakeholders; who they are, what they want from the event, and how they hope it will unfold. Ruud explains why we need to keep in mind those critical elements, and how to both manage expectations and surpass them. He also shares his thoughts on articulating thought leadership on stage, and what we can do to create behavior change from entry to exit. In addition, we learn how his business grew from offering a better understanding of The Design Canvas, to the creation of the Event Design Certificate program, and the creation of the  Event Design Handbook — all to help empower event organizers to create amazing, impactful gatherings. If you want to learn more about The Event Canvas, you can get it free along with the first 100 pages of the Event Design Handbook HERE. Three Key Takeaways: Thought Leadership isn't just about insights. It needs to shape those insights and focus them in ways that deliver behavior change. Thought Leaders should spend at least 1% of their total attendance time thinking about the event they are hosting, and how to best reach attending stakeholders. You don't have to have a Hollywood budget for a Thought Leadership event! The production quality simply needs to elevate the conversation taking place.

Haarlem105
Stichting Duinbehoud: ''voorzie de Formule1-auto's van katalysatoren''

Haarlem105

Play Episode Listen Later Apr 30, 2022 8:21


Marc Janssen, directeur van Stichting Duidbehoud, vertelt in Haarlem Vandaag dat hij erg teleurgesteld is over rechterlijke uitspraak dat het Formule1-evenement in dezelfde mate stikstof mag blijven uitstoten. ‘'Als de Formule1-auto's van katalysatoren worden voorzien zou er al veel minder worden uitgestoten'', stelt Janssen. Stichting Duinbehoud gaat de rechterlijke uitspraak verder bestuderen en gaat mogelijk in hoger beroep.

Andruck - Deutschlandfunk
Lorenz Maroldt, Susanne Vieth-Entus: "Klassenkampf"

Andruck - Deutschlandfunk

Play Episode Listen Later Apr 25, 2022 7:02


Janssen, Christinawww.deutschlandfunk.de, Andruck - Das Magazin für Politische LiteraturDirekter Link zur Audiodatei

Tweakers Partners - Podcast over Technologie
EY Tech Transformers - Cybersecurity met Jim Stolze

Tweakers Partners - Podcast over Technologie

Play Episode Listen Later Apr 25, 2022 52:18


Tweakers Partners introduceert een nieuwe podcastserie: EY Tech Transformers. Een serie over technologie en verandering met een centrale vraag: ‘Hoe draagt technologie bij tot een beter werkende wereld?'. In de eerste aflevering van dit drieluik staat Cybersecurity centraal. Digitale transformatie is natuurlijk geen eindig - maar een continu proces. Daarom is het goed om verder te kijken dan de bekende buzzwords en de theorie, door voorbeelden uit de praktijk te bespreken en deze te analyseren. Dat is precies wat de Tech Transformers podcast series doet. In deze eerste aflevering praat gastheer Jim Stolze met Joost Quist en Ramòn Janssen, beiden Cybersecurity experts bij EY, over hun ervaringen onderling en de vraagstukken van klanten op het gebied van Cybersecurity. See omnystudio.com/listener for privacy information.

Zakendoen | BNR
Diana Janssen (DDMA) over de toekomst van digitale marketing

Zakendoen | BNR

Play Episode Listen Later Apr 22, 2022 105:11


Worden consumenten voldoende beschermd tegen agressieve marketing? En wat is de toekomst van de reclamefolder? Diana Janssen, directeur van branchevereniging Data Driven Marketing Association, is te gast in BNR Zakendoen. Kees de Kort Elke dag, even over twaalf, bespreekt presentator Thomas van Zijl met macro-econoom en commentator Kees de Kort de economische stand van zaken. Ondernemerspanel Een MKB-bank naar Brits model moet financiering voor het MKB makkelijker maken, maar is dat eigenlijk wel nodig? En: een familieruzie in de bedrijfstop bij een groot bedrijf uit Genemuiden. Hoe voorkom je zakelijke ruzie bij een familiebedrijf? We gaan het allemaal bespreken in het ondernemerspanel. Te gast zijn: - Monique Ansink, eigenaar van Jumbo Spanbandenfabrikant; - Alinda Wit, oprichter en eigenaar van LovEvery Nederland. Pitches Elke vrijdag is het weer tijd voor jonge ondernemingen om zichzelf op de kaart te zetten. Dat doen zij via een pitch en het doorstaan van een vragenvuur. Vandaag is het de beurt aan Rick van Rijthoven, eigenaar van World of eMobility en Renske Wytzes, mede-oprichter van Flytz. Met beoordelaar Jacqueline van den Ende, mede-oprichter van Carbon Equity. Zakenpartner Ze studeerde rechten én bedrijfskunde, werd bedrijfsjurist bij Trustmoore en klom op tot managing director van de firma. Maar na acht jaar in de consultancy ging het roer om: ze werd algemeen directeur bij Pro Contact, waar recruiting en marketing hand in hand gaan. De Zakenpartner deze week is Yanouk Bierens, algemeen directeur van Pro Contact. Contact & Abonneren BNR Zakendoen zendt elke werkdag live uit van 12:00 tot 14:30 uur. Je kunt de redactie bereiken via e-mail en Twitter. Abonneren op de podcast van BNR Zakendoen kan via bnr.nl/zakendoen, of via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

Psound Bytes
Ep. 162 "Paying it Forward: Celebrating a Legacy of Helping Others With Psoriatic Disease"

Psound Bytes

Play Episode Listen Later Apr 19, 2022 42:36


Discover how the legacy of paying it forward began for four extraordinary One to One Program mentors - John Latella, Jaime Moy, Michel Tarabocchia and Jessica Houston. Hear their incredible stories about life with psoriasis and psoriatic arthritis from treatment choices to how they found help when they needed it most. Psound Bytes is supported by unrestricted educational grants from AbbVie, Amgen, Bristol Myers Squibb, Janssen, and Lilly. 

AP Audio Stories
J&J's Janssen settles with WVa for $99M in opioid lawsuit

AP Audio Stories

Play Episode Listen Later Apr 18, 2022 0:46


Opioid Trial West Virginia intro and voicer

Rheumnow Podcast
QD Clinics On PsA(QD186 - QD188)

Rheumnow Podcast

Play Episode Listen Later Apr 14, 2022 18:51


QD186 - When the Going Gets Good QD187 - Loss of Biologic Effect QD188 - PsA & LFTs RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty.

Elevate Maryland
Believin' in Evelyn w/ Janssen Evelyn

Elevate Maryland

Play Episode Listen Later Apr 9, 2022 52:01


Candace and Tom celebrate FIVE YEARS of podcasting by hosting a live interview with Howard County Council District 4 candidate Janssen Evelyn. He addressed why housing is one of his top priorities and the way in which art infuses itself into his life. Janssen also recounts some stories from the field as he works to become the first person of color to represent Downtown Columbia on the County Council.

Rheumnow Podcast
QD Clinics - Lessons from the clinic (QD 183-185)

Rheumnow Podcast

Play Episode Listen Later Apr 8, 2022 13:55


QD183 - Moll & Wright - Right or Wrong? QD184 - What to Do-Do-Do About the DIPs? QD185 - Rheum Comanagement of Psoriasis RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty.

EV News Daily - Electric Car Podcast
1430: 09 Apr 2022 | Elon Musk hosts 'Cyber Rodeo' At Austin Gigafactory

EV News Daily - Electric Car Podcast

Play Episode Listen Later Apr 8, 2022 17:23


Show #1430 Good morning, good afternoon and good evening wherever you are in the world, welcome to EV News Daily, you trusted source of EV information. It's Saturday 9th April, it's Martyn Lee here and I go through every EV story so you don't have to. TESLA CEO ELON MUSK HOSTS 'CYBER RODEO' PARTY TO OPEN AUSTIN FACTORY - On Thursday night, Tesla CEO Elon Musk spoke at a grand opening event for the electric vehicle maker's new $1.1 billion factory near the Austin airport in Texas. - At the event, he spoke about how massive the new factory is, and teased products that are still in development, including the Cybertruck, and a robotaxi that he promised would look quite futuristic. - Tesla aims to make 500,000 units of the Model Y in a single year in Austin - “In trailing twelve months, we've delivered over a million cars worldwide,” Musk said. “There's still a long way to go.” - “We're aiming to go to wide beta for almost all Full Self-Driving customers in North America this year,” - Musk said on Thursday night that the Model Y vehicles being produced in Texas feature what's known as a “structural pack,” meaning the cells in the cars' high voltage battery packs carry the load of the vehicle. Original Source : https://www.cnbc.com/2022/04/07/tesla-ceo-elon-musk-hosts-cyber-rodeo-party-to-open-austin-factory.html TESLA'S 4680 CELLS & STRUCTURAL PACK REVEALED AT CYBER RODEO - While Tesla CEO Elon Musk did reveal a few juicy bits of information at Tesla's Cyber Rodeo delivery party last evening, there wasn't a whole lot of "new material," and future plans, details, and dates were lacking. That said, tweets and videos from fans, owners, and investors attending the event delivered more compelling information. - Tesla had several unique displays prepared for the event, including one that revealed production-level 4680 battery cells manufactured at Giga Texas. - The text on the hanging metal plaque above reads:  “Made at Gigafactory Texas, our new tabless 4680 cell lowers the cost per kilowatt hour. We have everything we need under one roof to produce and assemble the first high-volume structural battery pack, using our fully integrated process. The structural pack greatly reduces the number of parts used in both the battery pack and the car, allowing our pack manufacturing line to be less than half the size of previous factories." Original Source : https://insideevs.com/news/578801/tesla-structural-pack-4680-cells-unveiled-cyber-rodeo/ TESLA OFFICIALLY OPENS TEXAS GIGAFACTORY - The milestone was achieved less than two years after Musk declared that Austin would be the site of the company's next Gigafactory and less than one year after Tesla officially moved its headquarters to Texas from California. - Tesla has said it expects to make 1.5 million vehicles in 2022, after producing slightly less than 1 million vehicles last year - The company has said it will hire up to 5,000 workers at an average salary of $47,147, with entry-level positions starting at $35,000. Today, Tesla employs about 10,000 people at its only US car plant in Fremont. Original Source : https://www.theverge.com/2022/4/8/23008731/tesla-texas-gigafactory-open-cybertruck-elon-musk TESLA WILL SELL ITS CYBERTRUCK NEXT YEAR, ELON MUSK SAYS - Tesla will begin producing its much-delayed electric pickup, the Cybertruck, next year along with numerous other new products, Elon Musk, the carmaker's chief executive, said late Thursday. - Tesla's chief executive has a long history of promising products that materialize later than he said they would or not at all, but his timeline for the Cybertruck is more definite than the one he gave to investors in January, when he said delivery in 2023 was “most likely.” - Delays in producing the Cybertruck have allowed rivals to come to market sooner with pickups, one of the most popular types of vehicle in the United States. Ford Motor is expected to begin delivering the Lightning, a battery-powered version of its F-150, this summer. Rivian's electric pickup went on sale late last year to rave reviews, but the company has had trouble ramping up production, a common problem for new car companies. - “This year is all about scaling up,” Mr. Musk said. “Next year, there is going to be a massive wave of new products.” Original Source : https://www.nytimes.com/2022/04/08/business/tesla-cybertruck-elon-musk.html TESLA DELIVERS FIRST MODEL Y VEHICLES WITH 4680 BATTERIES FROM GIGA TEXAS - On Friday, April 8, Elon Musk officially announced that the first production Model Y units were delivered. He thanked the Tesla team for their hard work. A few of the new Model Y owners already shared their joy with the community online. - Tesla technician Regan Janssen announced that she received the first Model Y with 4680 battery cells produced in Giga Texas on LinkedIn. Janssen happens to be an Engineering Process Technician at Tesla. She started her Tesla career just last month. Original Source : https://www.teslarati.com/tesla-gigafactory-texas-model-y-4680-battery/ CATL PAVES THE WAY FOR TESLA TO BEGIN BUILDING LFP-BASED VEHICLES AT GIGA BERLIN - CATL's $1.8 billion investment in Germany will supply carmakers in Germany with LFP batteries. Although CATL does not name any specific company, Tesla is probably the only carmaker in Germany that could use enough LFP batteries to justify the investment. Other carmakers, like Volkswagen, have agreements in place with Korean battery makers like SK Innovation and LG Energy Solutions while also investing in battery technologies on their own. - The initial capacity for the CATL battery factory is 8 GWh per year which is enough for 100,000 electric vehicles provided they have an 80 kWh battery. In the case of the Chinese Model Y with an LFP battery (Standard Range), the battery capacity sits at 60 kWh, so CATL would be able to equip more than 133,000 cars. - The first German-made batteries should go to partners by the end of the year when the plant should employ 1,500 workers. Original Source : https://www.autoevolution.com/news/catl-paves-the-way-for-tesla-to-begin-building-lfp-based-vehicles-at-giga-berlin-185971.html FORD BEGINS BUILDING E-TRANSIT VEHICLES FOR EUROPE Original Source : https://www.electrive.com/2022/04/08/ford-begins-building-e-transit-vehicles-for-europe/ CHINA'S BYD ENDS FULL COMBUSTION ENGINE CARS TO FOCUS ON ELECTRIC, PLUG-IN HYBRIDS Original Source : https://www.reuters.com/business/autos-transportation/chinas-byd-ends-combustion-engine-cars-focus-electric-2022-04-03/ NISSAN GIVES FIRST LOOK AT PROTOTYPE PRODUCTION PLANT FOR SOLID-STATE BATTERIES Original Source : https://www.autoexpress.co.uk/nissan/357742/nissan-gives-first-look-prototype-production-plant-solid-state-batteries QUESTION OF THE WEEK WITH EMOBILITYNORWAY.COM Mirror.co.uk: “An electric car owner has warned other EV drivers they can be fined for charging their vehicle in supermarket car parks. Electric vehicle owner Max Wilkinson - who is also a Cheltenham Councillor - recently bought a four-year-old hybrid Mini Countryman. He went home - but returned two hours later by which time the hybrid Mini was about half-charged. A week later Max received a penalty notice saying he'd been fined £90. Mr Wilkinson has paid the fine and doesn't dispute it. But he does think it doesn't quite make sense to restrict car charging to 90 minutes as well. - He said: “It seems illogical that quite a lot of EV and hybrid owners won't be allowed to spend enough time in the car park to get a full charge.” Email me any feedback to: hello@evnewsdaily.com It would mean a lot if you could take 2mins to leave a quick review on whichever platform you download the podcast. And  if you have an Amazon Echo, download our Alexa Skill, search for EV News Daily and add it as a flash briefing. Come and say hi on Facebook, LinkedIn or Twitter just search EV News Daily, have a wonderful day, I'll catch you tomorrow and remember…there's no such thing as a self-charging hybrid. PREMIUM PARTNERS PHIL ROBERTS / ELECTRIC FUTURE BRAD CROSBY PORSCHE OF THE VILLAGE CINCINNATI AUDI CINCINNATI EAST VOLVO CARS CINCINNATI EAST NATIONAL CAR CHARGING ON THE US MAINLAND AND ALOHA CHARGE IN HAWAII DEREK REILLY FROM THE EV REVIEW IRELAND YOUTUBE CHANNEL RICHARD AT RSEV.CO.UK – FOR BUYING AND SELLING EVS IN THE UK EMOBILITYNORWAY.COM/ OCTOPUS ELECTRIC JUICE - MAKING PUBLIC CHARGING SIMPLE WITH ONE CARD, ONE MAP AND ONE APP

Rheumnow Podcast
TNR- What Patients Say About PsA

Rheumnow Podcast

Play Episode Listen Later Apr 6, 2022 64:11


Tuesday Nite Rheumatology, held on April 5th, 2022 features a Patient Perspectives panel discussion, hosted by Dr. Jack Cush. PsA Panelists included: - Tena Brown - Christine Lindsay - Ashley Krivohlavek RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty.

Psound Bytes
Ep. 161 "I'm Unique Because of My Psoriasis"

Psound Bytes

Play Episode Listen Later Apr 5, 2022 22:52


Hear the amazing stories of NPF Youth Ambassadors Emme and Neel who share their "origin" of when they were first diagnosed, how they tell others about their disease, to how they cope with the positives and negatives of living with psoriasis and psoriatic arthritis. Both will inspire you to celebrate being unique! Psound Bytes is supported by unrestricted educational grants from AbbVie, Amgen, Bristol Myers Squibb, Janssen, and Lilly. 

Graceful Atheist Podcast
Luke Janssen: Recovering Evangelicals

Graceful Atheist Podcast

Play Episode Listen Later Apr 4, 2022 83:33


This week's guest is Luke J. Janssen, M.Sc., Ph.D., M.T.S., Professor Emeritus, Dept. Medicine, McMaster University, and co-host of the Recovering Evangelicals podcast. He is a scientist in medical research. During a faith crisis he began taking courses on theology which turned into an M.T.S degree. Luke tells his story in four 15 year phases: his early years as a nominal Reformed Christian, his young adulthood as a Pentecostal/Charismatic fundamentalist, a desconstruction phase, and where he is now, with a “small part of him that won't let go” and a belief in a creative force. Luke and his co-host, Boyd Blundell, cover many aspects of desconstruction on the Recovering Evangelicals podcast. They discuss various apologetic and scientific arguments and honestly reveal what they do an do not believe now and why. Links Website https://lukejjanssen.wordpress.com/ Recovering Evangelicals https://lukejjanssen.wordpress.com/recovering-evangelicals/ Interact Join the Deconversion Anonymous Facebook group https://www.facebook.com/groups/deconversion Full episode show notes https://gracefulatheist.com/2022/04/03/luke-janssen-recovering-evangelicals/ Secular Grace https://gracefulatheist.com/2016/10/21/secular-grace/ Deconversion https://gracefulatheist.com/2017/12/03/deconversion-how-to/ Deconstruction https://gracefulatheist.com/2017/12/03/deconversion-how-to/#deconstruction/ Attribution "Waves" track written and produced by Makaih Beats https://makaihbeats.net/ --- Send in a voice message: https://anchor.fm/gracefulatheist/message Support this podcast: https://anchor.fm/gracefulatheist/support

The Folly Coffee Podcast
Ep122 Category: People- Jonahan Janssen, Sales Manager Brother Justus Whiskey

The Folly Coffee Podcast

Play Episode Listen Later Apr 3, 2022 59:24


In this episode, Folly Rob sits down with Jonathan Janssen, Sales Manager at Brother Justus Whiskey. J Starting as a server at Upton 43, Jonathan has served in many roles including in the restaurant industry and is an advocate for mental health and change. Hear his story here. Enjoy! --- Send in a voice message: https://anchor.fm/follycoffeepodcast/message Support this podcast: https://anchor.fm/follycoffeepodcast/support

Rheumnow Podcast
QD Clinics - Lessons from the clinic (QD 178-182)

Rheumnow Podcast

Play Episode Listen Later Apr 1, 2022 60:03


QD178 - Your Psoriatic Questions from RNL2022 QD179 - Your Rheumatoid Questions from RNL 2022 QD180 - Your Lupus Questions from RNL 2022 QD181 - Your Spondyloarthritis Questions from RNL 2022 QD182 - Your Hot Topic Questions from RNL 2022 RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty.

Chicago Psychology Podcast
Mental Health at Work in Times of Crisis with Melissa Doman, MA

Chicago Psychology Podcast

Play Episode Listen Later Apr 1, 2022 37:38


On this episode of the Psychology Talk Podcast, Dr. Hoye is joined, once again, by Melissa Doman, MA. Melissa is an Organizational Psychologist, Former Clinical Mental Health Therapist, & Author of Yes, You Can Talk About Mental Health at Work (Here's Why And How To Do It Really Well). Melissa works with companies across industries around the globe – including clients like Microsoft, Salesforce, Siemens, Estée Lauder, & Janssen. She's been featured as a subject matter expert in Vogue, the BBC, CNBC, and Inc. Magazine about the Great Resignation, mental health at work conversations about the Ukraine Crisis, and more. Having lived abroad in South Korea, England, Australia and traveled to 45+ countries, Melissa calls upon her global experiences to inform how she works with companies around the world. She has one core goal: to equip companies, individuals, and leaders to have constructive conversations about mental health in the workplace. Her work and book aim to accomplish just that.On this episode, Melissa discusses leadership and mental health at work during difficult times: •Environmental, Social & Governance in the Workplace•Leadership during war time•Leadership during the pandemic•Melissa Doman's interview with Inc. Magazine•Ways to open up about mental health concerns Melissa Doman's Website: https://melissadoman.comMelissa's Interview with Inc. Magazine:https://www.inc.com/rebecca-deczynski/ukraine-crisis-supporting-employee-mental-health.htmlThe Psychology Talk Podcast is a unique conversation about psychology around the globe. Your hosts Dr. Scott Hoye and licensed clinical professional counselor Kyle Miller talk about psychology with mental health practitioners and experts to keep you informed about issues and trends in the industry.https://psych-talk.comhttps://www.instagram.com/psychtalkpodcast/

Resoundingly Human
Resoundingly Human: 2022 Franz Edelman Competition: Janssen

Resoundingly Human

Play Episode Listen Later Mar 29, 2022 18:32


This podcast is part of a special series featuring the 2022 finalist teams for the INFORMS Franz Edelman Award for Achievement in Advanced Analytics, Operations Research and Management Science, the most prestigious award for achievement in the practice of O.R. and advanced analytics. For more than four decades, the Edelman Award has recognized contributions that are transforming how we approach some of the world's most complex problems. Finalists for the Edelman Award have contributed to a cumulative impact of more than $336 billion since the award's inception, as well as countless other nonmonetary benefits. The winner of this year's award will be announced at the 2022 INFORMS Business Analytics Conference, April 3-5. Joining me for this episode are Dimitris Bertsimas, professor with the MIT Sloan School of Management and Najat Khan, Chief Data Science Officer and Global Head, Research and Development Strategy & Operations with Janssen Research and Development, LLC,  to discuss the finalist entry from the team at Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen). To accelerate the development of the Johnson and Johnson COVID-19 vaccine, the Research and Development Data Science team at Janssen worked with the Massachusetts Institute of Technology (MIT) to co-develop and refine a machine learning-based COVID-19 epidemiological disease spread model, building on MIT's DELPHI scenario analysis tool, capable of predicting future COVID-19 infection spread months in advance at a global level. This model enabled Johnson and Johnson to expedite a highly accurate clinical trial for the first single-dose COVID-19 vaccine, as well as gain valuable insight on virus variants.

Content creator to Money Maker podcast with Michelle Gifford
Ep 181 Creating a loyal following and profitable blog with Janssen from Every Day Reading

Content creator to Money Maker podcast with Michelle Gifford

Play Episode Listen Later Mar 29, 2022 40:32


Is blogging dead? Can you really make money from having a blog? Yes, my friend. I've told you this before, but today we get to hear from Janssen from Everyday Reading. She has a profitable blog, a loyal following, and she's just a joy. I love following her because she is so brilliant at what she does in growing her business. You're going to love this live interview that I did with Janssen. Janssen Bradshaw Website: https://everyday-reading.com/ Instagram: https://www.instagram.com/everydayreading/ Text "Money Maker" to 951-309-7885 to get my goal pages for the year and to track your monthly money making goals. Join my Money Makers coaching group for an amazing community, courses, and coaching. Visit iammichellegifford.com/moneymakers

One Heart Church
Janssen Ang | J.W.T.L

One Heart Church

Play Episode Listen Later Mar 27, 2022 28:00


Recorded live at One Heart Church (Port Lincoln) at our 10.30am service on the 20th of March, 2022.

NEI Podcast
E140 - (CME) Catch Me If You Can: Early Screening and Detection for Tardive Dyskinesia

NEI Podcast

Play Episode Listen Later Mar 23, 2022 53:58


In this episode, Dr. Andrew Cutler interviews Dr. Rajnish Mago on best practices for early detection and screening for tardive dyskinesia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD01 Learning Objectives: After completing this educational activity, you should be better able to: Conduct regular screenings for symptoms of tardive dyskinesia in patients with mood disorders and schizophrenia Employ evidence-based screening tools in the differential diagnosis of tardive dyskinesia, including the Abnormal Involuntary Movement Scale  Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.   Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours   Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented. Interviewer Andrew J. Cutler, MDClinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva  Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva Interviewee Rajnish Mago, MD  Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY  Clinical Assistant Professor, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA  Editor-in-Chief, Simple and Practical Medical Education  No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: March 23, 2022          CE credit expires: March 23, 2025

Spittin Chiclets
Spittin' Chiclets Episode 378: Featuring Sam Bennett + Cam Janssen

Spittin Chiclets

Play Episode Listen Later Mar 22, 2022 216:45


On Episode 378 of Spittin' Chiclets, the guys are joined by Sam Bennett and Cam Janssen. Sam joined (00:34:33) to discuss getting traded to Florida last season, his time in Calgary, the cars in Florida and tons more. But first, the guys open the show discussing all things NHL trade deadline. The guys break down all the big moves and non moves, plus give their insight for the final stretch run of the season. The fellas are then joined by old friend Cam Janssen (01:55:20) to talk St. Louis Blues, Kangaroos, hairlines and more. The guys wrap up with some Darryle Sutter quotes, movie talk, and the age old question…will Ovi beat Gretzky's scoring record?

PCE
ASCO Genitourinary Cancers Symposium, 2022: A Focus on Prostate Cancer

PCE

Play Episode Listen Later Mar 17, 2022 27:46


In this podcast, Dr. Alicia Morgans discusses recent data presented at the 2022 ASCO GU Cancers Symposium, including trials evaluating the use of first-line PARP inhibitors in combination with abiraterone for mCRPC, continuation of enzalutamide after progression, and imaging modalities as predictive and prognostic biomarkers. This activity is available for CE/CME credit. Claim your credit at pce.is/ascogu.Contributors: Dr Morgans has disclosed that she has received funds for research support from Atellas, AstraZeneca, Bayer, Myovant, and Pfizer, and consulting fees from AAA, Astellas, AstraZeneca, Bayer, Blue Earth, Clovis, Dendreon, Janssen, Lantheus, Merck, Myovant, Novartis, Pfizer, Sanofi, and Telix.Ms Martone has no relevant conflicts of interest to report. 

Overdrive by Rheumatology Network
Overdrive Update: Guselkumab for Treating Active Psoriatic Arthritis Part 2

Overdrive by Rheumatology Network

Play Episode Listen Later Mar 14, 2022 14:54


On this month's episode, I spoke with Soumya D. Chakravarty, MD, PhD, to discuss the growing body of clinical evidence evaluating joint efficacy, safety and patient-reported outcomes in patients with psoriatic arthritis receiving guselkumab. Time Stamps: 0:50: Can you tell me more about guselkumab and how it is used to treat patients with psoriatic arthritis?  3:32: What were the study designs and methods used in developing the DISCOVER-1 and DISCOVER-2 trials? 5:43: What were the primary (and any secondary) endpoints evaluated in these trials?  7:00: What were the results regarding efficacy, safety, and patient-reported outcomes that were presented at the ACR?  9:23: What does this clinical research mean for both rheumatologists and their patients?  12:07: Is there anything else you'd like our audience to know about guselkumab or Janssen before we wrap up?

2 Goalies 1 Mic
Episode 90 with Cam Janssen

2 Goalies 1 Mic

Play Episode Listen Later Mar 13, 2022 63:35


Cam Janssen joins the show to talk about the St. Louis Blues season, Jordan Binnington losing the starting job to Ville Husso. They also do a round table discussion on the Jack Eichel comments after the Sabres 3-1 win over the Vegas Golden Knights along with Ryan Drury, Kyle Quick, and Carson Gates. Also Heritage Classic talk.

SportsTalkLine
S2 Ep6: March Madness Predictions and Interview with College Basketball Coach John Janssen

SportsTalkLine

Play Episode Listen Later Mar 13, 2022 43:08


This week Joshua is joined by John Janssen, Head Coach of the La Sierra Univsitery Golden Eagles. We chat about  John getting started with his coaching career, how he didn't know he could do this as an actual job, and his desire for competition and how that stoked his coaching fire. Then Joshua and John switch gears and talk #NCAA March Madness and what we can expect from the tournament. We go a bit off-topic and dive into the #NBA as I find out John Janssen's favorite team is the Lakers. We have to talk some purple and gold and Lebron James before we head to #WeTheNorth and my favorite team. Next, we get into John's playing career after college and what he experienced playing overseas. You won't ever guess what he was covered in after a game in Uraguay. We get into some more stories abroad before getting back to the if North American Basketball will ever have that cult following it does elsewhere. I also asked John about his brother... Sorry... Baby brother, Casey Janssen and how sports influenced their life growing up. Finally, I get Johns's picks for the NCAA March Madness tournament! Make sure to check out www.sportstalkline.com for all of the great coverage and stories! Thanks to Don Andrews and "The Matinee" for the beautiful introduction. Follow your host on Twitter @JoshuaGriffith0 for all the latest news, as Sports Talk Line will cover you for the 2022 #MLS Season. Leave a comment, like a video, and subscribe to the Sports Talk Line Youtube Channel if you don't already.

Psound Bytes
Ep. 160 "Navigating Insurance Denials"

Psound Bytes

Play Episode Listen Later Mar 8, 2022 20:46


Ever face the frustration of insurance denials for psoriatic disease treatments you need? Hear Elle Hurley, a member of the Patient Navigation Center Team and Sam Cox, State Government Relations Manager, offer tips to address insurance denials from steps you can take, what to document, and who to contact if an external appeal is needed. This episode is supported by unrestricted educational grants from Bristol Myers Squibb, Janssen and Lilly. 

The Every Nation Podcast
Janssen Morados: The Word of God Endures Forever

The Every Nation Podcast

Play Episode Listen Later Mar 7, 2022 11:15


What is the right and righteous response to the knowledge of God's Word? Janssen Morados, Executive Director of Victory Metro Manila in the Philippines, preaches on the most useful tool for responding to what God says and who he is.

FirstTake on Pharma - Pharma News and Analysis Podcast
The FirstTake Podcast – Where next for gene editing?

FirstTake on Pharma - Pharma News and Analysis Podcast

Play Episode Listen Later Mar 3, 2022 11:39


On this week's episode FirstWord Pharma PLUS editors Virginia Li, Michael Flanagan and Simon King discuss key developments in the field of gene editing, the approval of Janssen and Legend Biotech's Carvykti for multiple myeloma and whether interchangeability status will have a meaningful impact on future US market for Humira biosimilars.

ASCO Daily News
#GU22: Striving for Treatment Equity in GU Cancers

ASCO Daily News

Play Episode Listen Later Mar 3, 2022 5:59


Dr. Neeraj Agarwal, ASCO Daily News editor-in-chief, and director of the Genitourinary Cancers Program at the University of Utah's Huntsman Cancer Institute, highlights key studies on disparities in GU cancers featured at the 2022 ASCO Genitourinary Cancers Symposium. Transcript:   ASCO Daily News: Hello and welcome to the ASCO Daily News Podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. In today's episode, Dr. Neeraj Agarwal, the ASCO Daily News editor in chief, will highlight compelling studies on disparities in GU cancers featured at the 2022 ASCO Genitourinary (GU) Cancers Symposium. Dr. Agarwal has no conflicts relating to the topic of this episode and his full disclosures are available in the show notes. Disclosures of all guests on the podcast can be found in our transcripts at asco.org/podcasts.  Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Cancers Program and professor of medicine at the University of Utah Huntsman Cancer Institute. So, I'd like to start with Abstract 20 presented by Dr. Alicia Morgans from the Dana-Farber Cancer Institute. Multiple population-based studies have reported a higher incidence of prostate cancer in Black men. [This disease] usually presents with aggressive features, at an earlier age, and is associated with higher mortality rates compared to White men. In contrast, multiple reports suggest that Black men with advanced prostate cancer also have better survival outcomes to novel hormonal therapies compared to White men. Using electronic medical records retrieved from a urology specialty database, Dr. Alicia Morgans investigated whether improved survival outcomes in Black men treated with enzalutamide are due to better responses compared to White men. So eligible patients, who are chemotherapy and abiraterone naive and included 214 Black men and 1,332 White men with advanced prostate cancer.    Reserves from a multivariate analysis were adjusted for baseline characteristics and indicated a statistically significant delay in clinical progression-free survival for Black men treated with enzalutamide compared to White men. This supports the argument that given equal access to care, Black men may respond similarly or better than White men to treatment for advanced prostate cancer. The next abstract addressing disparities in GU cancers was Abstract 444 presented by Dr. Samuel Washington from UCSF School of Medicine. Radical cystectomy remains the gold standard for muscle-invasive bladder cancer, yet confers significant health care costs. Prior work on the impact of cost commonly relied on comparisons by insurance status and income. Few studies have examined the relationship between the net worth of the household and the encounter type, such as outpatient versus inpatient encounters. As we also know, outpatient encounters are usually cheaper or less expensive than more expensive inpatient encounters.    So, in this intriguing and novel study, Dr. Samuel Washington presented a real-world analysis of demographics, household net worth, health plan cost, out-of-pocket cost, and total health care cost accrued from the day of admission to 90 days after radical cystectomy for muscle-invasive bladder cancer. This was the largest study of its kind and included more than 140,000 commercially insured patients to examine variations in health care utilization by net worth in 90 days after radical cystectomy. Results are very interesting and indicate that patients with lower household net worth were at a greater risk for an acute inpatient encounter and thus higher medical cost, while patients with greater household net worth had greater odds of office visits or outpatient encounters, which are associated with lower cost. So, these findings indicate that a lower household network continues to be a significant factor in health care utilization and higher health care costs, even within a commercially insured patient population. So very interesting findings indeed and these findings definitely should pay for further future studies involving or looking at this aspect of disparities. Thank you very much for your kind attention.    ASCO Daily News: That was Dr. Neeraj Agarwal of the University of Utah's Huntsman Cancer Institute. If you've enjoyed this series, please take a moment to rate and review us wherever you get your podcasts.     Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Medivation/Astellas, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Merck, Novartis, lily, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences      Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, ORIC Pharmaceuticals, CRISPR therapeutics, and Arvinas      Disclaimer: The purpose of this podcast is to educate and to inform this is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

Arroe Collins
Sarah Janssen Releases The All New 2022 World Almanac

Arroe Collins

Play Episode Listen Later Mar 3, 2022 11:16


“The World Almanac has been the source for definitive data and answers to questions on any subject since 1868,” said Sarah Janssen, executive editor of The World Almanac. “In a year of major transitions, the new edition of The World Almanac documents the rapidly shifting world to give a source of historic perspective and new understanding to any curious reader.”

ASCO Daily News
#GU22: Advancing Care for Patients With mHSPC

ASCO Daily News

Play Episode Listen Later Mar 2, 2022 5:44


Dr. Neeraj Agarwal, ASCO Daily News editor-in-chief, and director of the Genitourinary Cancers Program at the University of Utah's Huntsman Cancer Institute, shares key takeaways from the practice-changing ARASENS trial in mHSPC, featured at the 2022 ASCO Genitourinary Cancers Symposium.   Transcript: ASCO Daily News: Hello, and welcome to the ASCO Daily News podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. Today in our continuing coverage of the 2022 ASCO Genitourinary (GU) Cancer Symposium. Dr. Neeraj Agarwal, the editor in chief of the ASCO Daily News will share key takeaways from the practice-changing ARASENS trial, which showed promising results in metastatic hormone-sensitive prostate cancer. Dr. Agarwal has no conflicts relating to the topic of this episode and his full disclosures are available in this show notes. Disclosures of all guests on the podcast can be found in our transcripts at asco.org/podcasts. Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News podcast. I'm Dr. Neeraj Agrawal, the director of the Genitourinary Cancers Program and professor of medicine at the University of Utah Huntsman Cancer Institute. Let's discuss the results of the practice-changing ARASENS trial in patients with metastatic castration-sensitive prostate cancer as presented at the 2022 ASCO GU Symposium. This abstract, Abstract 13, was presented by Dr. Matthew Smith from the Massachusetts General Hospital and Hartford Medical School. ARASENS is a randomized phase 3 trial evaluating the efficacy and safety of darolutamide, a novel hormonal therapy, plus ADT (antiandrogen therapy) plus docetaxel versus placebo plus ADT plus docetaxel in patients with metastatic castration-sensitive prostate cancer. Randomization was stratified by the extent of disease and alkaline phosphatase levels, below versus upper limit of normal or above. It is important to know that this study only included patients that were eligible for ADT and docetaxel chemotherapy, to begin with. The primary endpoint was overall survival with multiple secondary endpoints, including time to CRPC (castration-resistant prostate cancer), time to pain progression, time to first symptomatic skeletal event, and time to start off the next anti-neoplastic therapy, and safety. A total of 1,306 patients were randomly assigned to triplet therapy with darolutamide plus ADT plus docetaxel versus placebo plus ADT plus docetaxel. Baseline characteristics were well balanced between the treatment arms. Analysis of the primary endpoint was pre-specified. After, 533 events had occurred results show the primary endpoint of this study was met with a significant improvement in overall survival and a 32.5% reduction in risk of death for patients on the triplet therapy on for darolutamide plus ADT plus docetaxel versus placebo plus ADT plus docetaxel. It is important to know that the triplet therapy improved overall survival, despite 76% of patients in the control arm having received the next life-prolonging therapy. Subgroup analysis indicates consistent benefit across the 3 specified groups. Secondary endpoints also were favored by the triplet therapy combination over the control arm. While this study offers an additional excellent option for our patients with metastatic cancer-sensitive prostate cancer in older populations, the use of docetaxel may be a significant limitation to this triplet combination. In addition, and importantly, this study did not answer the question of whether adding docetaxel chemotherapy to the ADT plus novel hormonal therapy backbone will also improve survival. With the advent of multiple doublets and triplet combinations in recent years, as we saw in the form of ADT plus enzalutamide ADT plus apalutamide in the recent years, it is very important to find biomarkers that may predict response to these treatment options, which will allow personalization of therapy with that. I would like to conclude this podcast on the ARASENS trial. Thank you very much for your kind attention. ASCO Daily News: You've been listening to Dr. Neeraj Agarwal of the University of Utah's Huntsman Cancer Institute. Thanks for joining us today. If you're enjoying the content on the podcast, please take a moment to rate and review us wherever you get your podcasts. Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Medivation/Astellas, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Merck, Novartis, lily, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, ORIC Pharmaceuticals, CRISPR therapeutics, and Arvinas Disclaimer: The purpose of this podcast is to educate and to inform this is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Arroe Collins
Sarah Janssen Releases The All New 2022 World Almanac

Arroe Collins

Play Episode Listen Later Mar 2, 2022 11:16


“The World Almanac has been the source for definitive data and answers to questions on any subject since 1868,” said Sarah Janssen, executive editor of The World Almanac. “In a year of major transitions, the new edition of The World Almanac documents the rapidly shifting world to give a source of historic perspective and new understanding to any curious reader.”

Arroe Collins
Sarah Janssen Releases The All New 2022 World Almanac

Arroe Collins

Play Episode Listen Later Mar 2, 2022 11:16


“The World Almanac has been the source for definitive data and answers to questions on any subject since 1868,” said Sarah Janssen, executive editor of The World Almanac. “In a year of major transitions, the new edition of The World Almanac documents the rapidly shifting world to give a source of historic perspective and new understanding to any curious reader.”

Combinate Podcast - Med Device and Pharma
022 - "What Chapter are you in?" with Susan Neadle

Combinate Podcast - Med Device and Pharma

Play Episode Listen Later Mar 2, 2022 83:04


On this episode, we were joined by Susan Neadle. If you work on Combination Products, Susan is someone you need to know. Her and I discuss: Her career starting in consumer health and pivoting into Medical Devices then Pharmaceuticals Design to Value, Design Excellence and Process Excellence The History of Combination Products regulation and what it was like implementing 21 CFR Part 4 as it was revealed. Creating future plans using tools like the Merlin Exercise, and Future/Back Vocabulary in Combination Products AAMI TIR 48 and TIR 105 Her involvement in ASTM, AAMI, ISPE, FPIA, DIA, AFDA, TOPRA and RAPS Prioritization, Passion and her upcoming book ------------------------------------- Susan Neadle, MS, BS, FAAO is a recognized international Combination Products and Medical Device expert with over 35 years of industry experience. Networked, published, highly active in numerous industry groups and with links to a number of teaching institutions, Susan brings deep knowledge, and genuine passion for sharing that knowledge, with others. Susan's leadership, innovation, and best practices have been recognized with multiple awards, including the Johnson Medal, Johnson & Johnson's highest honor for excellence in Research & Development, and most recently, as a Finalist in TOPRA's 2021 Awards for Regulatory Affairs Excellence. She is Principal Consultant and President of Combination Products Consulting Services LLC, applying her extensive leadership and technical skills and experience to provide hands-on design-to-value, program management, quality & compliance, and regulatory consulting services, for pharmaceutical, biotech and medical device industries. Among her many significant industry affiliations and contributions, she serves as Chair of the ISPE Combination Products CoP, lead author on the ASTM International Combination Products Standard Committee, and teaches a Master's Curriculum on Combination Products at University of Maryland Baltimore Campus. Most recently, Susan served as Head of Combination Products, Medical Devices, Digital Health & IVD Regulatory Affairs at Amgen, providing strategic leadership in global combination products/ device regulatory development and portfolio/project management from initial clinical investigation through registration and commercial lifecycle. She served as an advisor for internal regulatory policy priorities, health authority engagement and submissions approaches through strategic engagement and mentoring of colleagues for individual projects and portfolio. She led interactions with multiple global health authorities, and served as a catalyst for external consortium deliverables and strategic direction. Susan retired from Johnson & Johnson. Her distinguished career there of more than 25 years included integral leadership roles in R&D, Quality Engineering, Design-to-Value, Risk Management and Quality Systems, spanning pharmaceuticals, medical devices, and consumer health sectors, including strategic Enterprise leadership as Chair of J&J's Design Council, advancing world-class practices in customer-centric product/process design and development. She led the team that defined and successfully implemented the globally integrated business model to meet Combination Products regulations for Janssen.

ASCO Daily News
#GU22: Learning From the PROpel and MAGNITUDE Trials

ASCO Daily News

Play Episode Listen Later Mar 1, 2022 10:08


Dr. Neeraj Agarwal, ASCO Daily News editor-in-chief, and director of the Genitourinary Cancers Program at the University of Utah's Huntsman Cancer Institute, shares key takeaways from the PROpel and MAGNITUDE trials in mCRPC, featured at the 2022 ASCO Genitourinary Cancers Symposium.   Transcript: ASCO Daily News: Hello and welcome to the ASCO Daily News Podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. Today, in our continuing coverage of the 2022 ASCO Genitourinary (GU) Cancers Symposium, Dr. Neeraj Agarwal, the editor-in-chief of the ASCO Daily News will highlight promising advances in metastatic castration-resistant prostate cancer. Dr. Agarwal has no conflicts relating to the topic of this episode, and his full disclosures are available in the show notes. Disclosures of all guests on the podcast can be found in our transcripts at asco.org/podcasts.   Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Cancer Program, and professor of medicine at the University of Utah Huntsman Cancer Institute, and editor in chief of the ASCO Daily News. I'd like to start with the PROpel trial followed by a discussion on the MAGNITUDE trial. So, Abstract 11 was on the results of the PROpel trial and presented by Dr. Fred Saad from the University of Montreal. PROpel is a randomized phase 3 trial, which evaluated the efficacy and safety of olaparib, a PARP inhibitor plus abiraterone versus this placebo plus abiraterone in the first-line metastatic castration-resistant prostate cancer setting. Patients were allowed to have docetaxel chemotherapy is given in a metastatic castration-sensitive prostate cancer setting. Enrollment in the study was independent of the effects in the homologous recombination repair pathway. The primary endpoint was investigator-assessed radiographic progression-free survival (PFS) with multiple secondary endpoints, including overall survival and safety.   Approximately 800 patients were randomly assigned to the novel combination of olaparib plus abiraterone or placebo plus abiraterone. Baseline characteristics were well-balanced between the treatment arms, including homologous recombination repair or HRR mutation status. At the pre-planned interim analysis results show the trial meets its primary endpoint with significant improvement in radiographic PFS for all patients receiving the combination therapy versus control, regardless of the presence of homologous recombination repair gene mutations. Median PFS was 24.8 months versus 16.6 months for patients receiving olaparib plus abiraterone versus placebo plus abiraterone respectively with the hazard ratio of 0.66, and a P < 0.0001. This translates into a 34% reduction in risk of progression or death. Overall survival results are still immature with only 29% [of patients experiencing events] thus far. It is interesting that even patients deemed negative for homologous recombination repair gene mutations showed significant improvement in radiographic PFS when treated with the combination of olaparib plus abiraterone versus placebo plus abiraterone.   Regarding the adverse effects, they were what you would expect from the combination of a PARP inhibitor, such as olaparib and abiraterone. We saw a higher sequence of all great events of anemia, fatigue, and nausea in the combination arm. While anemia was the only grade 3-4 adverse event observed at a significantly high frequency in the combination arm. It is also important [that] we get a better understanding of the molecular mechanism by which patients who are homologous recombination repair mutation-negative are benefiting from the combination treatment as well.   The next trial in this context, or this team, was the MAGNITUDE trial. Abstract 12 was presented by Dr. Kim Chi from British Columbia Cancer Center in Vancouver, Canada. MAGNITUDE is a randomized phase 3 trial evaluating the efficacy and safety of niraparib plus abiraterone plus placebo plus abiraterone in the first-line metastatic castration-resistant prostate cancer setting. The study population was slightly different from what we saw in PROpel trial. Taxane chemotherapy, as well as novel hormonal therapy, was allowed in metastatic castration-sensitive prostate cancer, as well as a prior novel hormonal therapy was allowed in the non-metastatic castration-resistant prostate cancer.   Also, patients were allowed up to 4 months of treatment with abiraterone in the first-line metastatic castrate-resistant prostate cancer. Prospective selection of patients with, and without homologous recombination repair (HRR) gene mutations were required. The primary endpoint was radiographic PFS by central review with multiple secondary endpoints, including overall survival and safety. A pre-specified fertility analysis was planned after enrolling 233 patients who were randomly assigned to niraparib plus abiraterone or placebo plus abiraterone. Evaluation of fertility was based on the composite PFS of PSA or radiographic progression, whichever occurred first. The pre-planned fertility analysis showed no benefit in the biomarker negative cohort. And thus the trial did not pursue further enrollment of those patients who were not positive for homologous recombination repair gene mutations.   Coming to the HRR positive cohort, 423 patients were randomly assigned to either niraparib plus abiraterone or placebo plus abiraterone. At the pre-planned interim analysis primary endpoint was met with a significant improvement in radiographic PFS for BRCA1 and BRCA2 and all patients who are homologous recombination repair mutation-positive, receiving the novel combination of niraparib plus abiraterone. Overall survival results are still immature. It is important to note that in the patients who are HRR positive, approximately 50% were BRCA1 and 2 positive. And these patients clearly derived the most benefit with a combination with an approximate 47% reduced risk of death. And if you look at other patients who are biomarker positive, there was a clear benefit and a significant improvement in median PFS (radiographic progression-free survival) with a hazard ratio of 0.73, which translates to a 27% reduction in the risk of death or progression. With the caveat of subgroup analysis, being underpowered following groups of patients seem to derive less benefit with the combination than the overall cohort with the combination of niraparib plus abiraterone. And these patients included patients who were age 65 or younger, or less than age 65, patients with visceral metastatic disease, patients with prior abiraterone or taxane chemotherapy, [and] patients who had a PSL level below the median, and patients with non-BRCA homologous recombination repair mutations.   In conclusion, the combination of niraparib plus abiraterone shows a significant improvement in the radiographic PFS for patients who are HRR positive in the first-line metastatic CRPC. Based on the available data in the public domain, without any doubt that both PROpel and MAGNITUDE trials established a combination of a PARP inhibitor with abiraterone in the first-line metastatic CRPC setting for patients who are positive for HRR mutation improve radiographic progression-free survival. Even though overall survival data are immature for both trials, I expect both combinations will be approved by the U.S. Food and Drug Administration in the near future and will be available to our patients. Regarding the HRR negative cohort in the PROpel trial, which also seems to derive significant benefit with the combination of abiraterone plus olaparib, I'm looking forward to the data on confirmation of HRR negative status by tissue-based genomic profiling results in the full-length publication which we expect to be published soon. If indeed confirmed by the tissue-based genomic profiling, I see the combination of abiraterone plus olaparib to be a reasonable option in the patients who are HRR negative in the first-line metastatic CRPC setting.   With this, I would like to conclude my discussion on the 2 practice-changing trials presented in the 2022 ASCO GU meeting, which were the PROpel and MAGNITUDE trials. Thank you very much for your kind attention. ASCO Daily News: That was Dr. Neeraj Agarwal of the University of Utah's Huntsman Cancer Institute. Thanks for joining us today. If you're enjoying the content on the podcast, please take a moment to rate and review us wherever you get your podcast.   Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Medivation/Astellas, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Merck, Novartis, lily, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, ORIC Pharmaceuticals, CRISPR therapeutics, and Arvinas Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.